![Jake Nunn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jake Nunn
Directeur/Membre du Conseil chez
ADDEX THERAPEUTICS LTD
Fortune : 12 926 $ au 31/05/2026
Profil
Jake R.
Nunn is an Independent Non-Executive Director at Addex Therapeutics Ltd. since 2018, a Director at Humanetics Corp.
since 2022, an Independent Director at Zenas BioPharma, Inc. since 2024, a Member of the CFA Society of San Francisco, and a Partner at SR One Capital Management LP since 2024.
Former roles include Director at TriVascular, Inc., Director at Hyperion Therapeutics, Inc. from 2009 to 2015, Non-Executive Director at Hexima Ltd. from 2021 to 2023, Director at Nicox Ophthalmics, Inc., Independent Director at Trivascular Technologies, Inc. from 2008 to 2016, Director at Trivascular2, Inc., Director at Transcept Pharma, Inc. from 2009 to 2011, Independent Director at Dermira, Inc. from 2011 to 2020, Director at Qool Therapeutics, Inc. from 2019 to 2021, Non-Executive Director at Oventus Medical Ltd., Independent Director at Regulus Therapeutics, Inc., Independent Director at Trevena, Inc. from 2013 to 2024, Portfolio Manager at Franklin Resources, Inc., Portfolio Manager at Franklin Templeton Investments Corp.
from 1998 to 2000, Principal at MPM BioEquities Adviser LLC from 2001 to 2006, Investment Banker at Alex.
Brown & Sons, Inc. from 1994 to 1996, Partner at NEA Management Co. LLC.
from 2006 to 2018, and Partner at New Enterprise Associates, Inc. from 2006 to 2019.
Education includes undergraduate studies at Dartmouth College and an MBA from Stanford Graduate School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/03/2026 | 219 561 ( 0,1 % ) | 12 926 $ | 31/05/2026 | |
-.--% | 12/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Jake Nunn
| Sociétés | Poste | Début |
|---|---|---|
| ADDEX THERAPEUTICS LTD | Directeur/Membre du Conseil | 01/06/2018 |
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 01/01/2023 |
Humanetics Corp.
 Humanetics Corp. Pharmaceuticals: MajorHealth Technology Develops and commercializes oncology, inflammatory diseases & biodefense drugs | Directeur/Membre du Conseil | 09/08/2022 |
CFA Society of San Francisco
 CFA Society of San Francisco Miscellaneous Commercial ServicesCommercial Services Provides educational services | Corporate Officer/Principal | 22/07/2009 |
Anciens postes connus de Jake Nunn
| Sociétés | Poste | Fin |
|---|---|---|
| TREVENA, INC. | Directeur/Membre du Conseil | 05/11/2024 |
| HEXIMA LIMITED | Directeur/Membre du Conseil | 05/09/2023 |
Qool Therapeutics, Inc.
 Qool Therapeutics, Inc. BiotechnologyHealth Technology Develops non-invasive temperature management therapies to induce therapeutic hypothermia | Directeur/Membre du Conseil | 01/06/2021 |
| DERMIRA, INC. | Directeur/Membre du Conseil | 20/02/2020 |
New Enterprise Associates, Inc.
 New Enterprise Associates, Inc. Financial ConglomeratesFinance Provides investment services | Corporate Officer/Principal | 01/01/2019 |
Formation de Jake Nunn
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
65
Relations au 1er degré
24
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 24 |
|---|---|
Franklin Resources, Inc.
 Franklin Resources, Inc. Investment ManagersFinance Operates as a holding company which provides investment management services | Finance |
Franklin Templeton Investments Corp.
 Franklin Templeton Investments Corp. Investment ManagersFinance FTIC’s equity strategies seek to identify stocks it believes to be significantly undervalued in markets across the globe. The strategies are managed in accordance with Sir John Templeton’s investment philosophy and approach, which are based on three tenets: value, patience, and bottom-up stock selection. By combining time-proven fundamental analysis with original research, the investment team searches for companies that meet their criteria of quality and valuation. | Finance |
MPM BioEquities Adviser LLC
 MPM BioEquities Adviser LLC Investment ManagersFinance MPM BioEquities Adviser focuses exclusively on global life sciences investments. The firm invests in biotechnology, specialty pharmaceuticals, medical technology and related companies that provide innovative medical products and services to the healthcare industry. They invest across all geographies, stages of development and therapeutic areas. MPM focuses on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data and the achievement of early commercial success, and on reinvigorating commercial platforms with potentially high growth assets. MPM BioVentures I (BB BioVentures, MPM BioVentures Parallel Fund) is a family of funds that was launched in 1997 and is no fully committed with 75% of its investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio consists of 26 companies with investments ranging from $5 million to $20 million per company. Within the biotechnology sector, the funds' investments are split between companies focused on therapeutics and enabling technologies. About 80% of the funds' assets are invested in US companies and 20% in European companies. The MPM BioVentures II family of funds closed in the first quarter of 2000. The funds consist of investments in biotechnology, medical devices and other healthcare related fields. The MPM BioVentures II has invested in 35 companies, with investments ranging from $10 million to $50 million. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. 85% of the funds' investments are in US companies and 15% are in European and Asian companies. The MPM BioVentures III Fund closed in December of 2002. The fund holds a portfolio of 39 companies, 85% of which are focused on biotechnology and pharmaceutical products and 15% are focused on medical devices and life science tools. The fund's balanced portfolio of early-, mid- and late-stage companies includes investments in public companies through PIPE transactions. The MPM BioVentures IV family of funds was launched in the second quarter of 2006. The funds hold a portfolio of 18 companies with investments ranging from $5 million to $36 million. About 75% of the funds' investments focus on biotechnology and pharmaceutical products and 25% focus on medical device companies. About 25% of the funds' investments have been made outside the US, including investments in Asia and Europe. The MPM BioVentures IV family of funds serves as the lead investor in a majority of its investments and takes an active role as a board member on its portfolio companies' boards of directors. | Finance |
TriVascular, Inc.
 TriVascular, Inc. Medical SpecialtiesHealth Technology Develops and manufactures medical devices | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Hexima Ltd.
 Hexima Ltd. BiotechnologyHealth Technology Engages in research and development of plant-derived proteins for treatment of fungal nail infections and provides commercial property services | Health Technology |
Nicox Ophthalmics, Inc.
 Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Health Technology |
Dartmouth College
 Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alex. Brown & Sons, Inc.
 Alex. Brown & Sons, Inc. Investment Banks/BrokersFinance Provides investment and investment banking services to individuals and entities | Finance |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements. | Finance |
Addex Therapeutics Ltd.
 Addex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs | Health Technology |
Trevena, Inc.
 Trevena, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by central nervous system | Health Technology |
CFA Society of San Francisco
CFA Society of San Francisco Miscellaneous Commercial ServicesCommercial Services Provides educational services | Commercial Services |
Trivascular Technologies, Inc.
 Trivascular Technologies, Inc. MiscellaneousMiscellaneous Operates as a holding company | Miscellaneous |
Trivascular2, Inc.
 Trivascular2, Inc. Medical SpecialtiesHealth Technology Develops medical devices | Health Technology |
Regulus Therapeutics, Inc.
 Regulus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in discovering and developing of drugs | Health Technology |
Humanetics Corp.
Humanetics Corp. Pharmaceuticals: MajorHealth Technology Develops and commercializes oncology, inflammatory diseases & biodefense drugs | Health Technology |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products to patients living with chronic skin conditions | Health Technology |
Stanford Graduate School of Business
 Stanford Graduate School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Qool Therapeutics, Inc.
Qool Therapeutics, Inc. BiotechnologyHealth Technology Develops non-invasive temperature management therapies to induce therapeutic hypothermia | Health Technology |
Oventus Medical Ltd.
 Oventus Medical Ltd. Medical SpecialtiesHealth Technology Develops oral appliances for the treatment of obstructive sleep disordered and snoring | Health Technology |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Finance |
New Enterprise Associates, Inc.
New Enterprise Associates, Inc. Financial ConglomeratesFinance Provides investment services | Finance |
